CinCor Pharma is a biotechnology business based in the US. CinCor Pharma shares (CINC) are listed on the NASDAQ and all prices are listed in US Dollars. CinCor Pharma employs 19 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $29.06 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $25.59 |
| 200-day moving average | $25.14 |
| Wall St. target price | $41.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.06 from 2023-03-03
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-22) | N/A |
|---|---|
| 2 years (2022-07-26) | 26.35% |
| 3 years (2021-07-22) | N/A |
| 5 years (2019-07-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -15.25% |
| Return on equity TTM | -26.91% |
| Profit margin | 0% |
| Book value | $11.86 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting CinCor Pharma to pay a dividend over the next 12 months.
You may also wish to consider:
CinCor Pharma, Inc. , a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc. .
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.